Calidi Biotherapeutics (CLDI) Stock Price
Calidi Biotherapeutics Price
Calidi Biotherapeutics's net margin stands at -56,504.4%, down from -2,435.0% several years earlier. Analysts set a median price target of 1.53 USD, implying 61.1% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.
Calidi Biotherapeutics stock price
Calidi Biotherapeutics business model & stock analysis
Frequently asked questions about Calidi Biotherapeutics
Analysts currently set an average price target of 1.53 USD for the Calidi Biotherapeutics stock (median: 1.53 USD), implying +61.1 % versus the latest price. The consensus is based on 8 analyst ratings.
7 analysts currently rate the Calidi Biotherapeutics stock: 6 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Calidi Biotherapeutics share trades at 0.85 EUR (0.95 USD).
The revenue cannot currently be calculated for Calidi Biotherapeutics.
The expected profit of Calidi Biotherapeutics is -57.41 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Calidi Biotherapeutics is currently -0.01. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Calidi Biotherapeutics stock.
The P/S cannot be calculated for Calidi Biotherapeutics currently.
The Eulerpool Quality Score for Calidi Biotherapeutics is 2/10.
The ISIN of Calidi Biotherapeutics is US3207034089. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Calidi Biotherapeutics is CLDI. The ticker symbol is used to trade Calidi Biotherapeutics shares on the stock exchange.
Calidi Biotherapeutics stock
Calidi Biotherapeutics Peer Group
All fundamentals and in-depth analysis of Calidi Biotherapeutics
Our stock analysis for Calidi Biotherapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Calidi Biotherapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.